New treatment option for adults with generalized anxiety disorder in Japan
- Effexor approved for generalized anxiety disorder
- New treatment available in Japan
- Viatris expands healthcare options
Viatris has announced the approval of Effexor (venlafaxine hydrochloride) in Japan for the treatment of adults with generalized anxiety disorder (GAD). This marks an important step for the company in broadening its portfolio of therapeutic options. Effexor is already recognized in several countries for its efficacy in treating anxiety and depression.
Generalized anxiety disorder affects a significant number of adults, leading to persistent feelings of worry and fear. The approval of Effexor provides a new treatment option that could improve quality of life for those affected. For healthcare providers in Japan, this approval means more choices for managing patients suffering from GAD.
Viatris emphasizes its commitment to addressing unmet healthcare needs through innovative treatments. With the introduction of Effexor, patients in Japan will have access to an established medication that has shown effectiveness in managing anxiety symptoms, thereby enhancing mental health care options in the country.
